Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis
Kidney International · 2024
DOI: 10.1016/j.kint.2024.06.003 ↗Kurz gefasst
Leserbrief in der Zeitschrift Kidney International, 2024. Verfasst von Takayuki Hamano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Department of Nephrology, The University of Osak…. Hauptthemen laut MEDLINE: Renal Dialysis, Phosphates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Astellas Pharma, Bayer.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Department of Nephrology, The University of Osaka Graduate School of Medicine, Osaka, Japan.
- Department of Medicine, Ikegami General Hospital, Tokyo, Japan; Division of Nephrology and Kidney Center, Kobe University School of Medicine, Kobe, Japan; Division of Nephrology, Endocrinology and Metabolism, Tokai Univ…
Förderung
- Astellas Pharma
- Bayer
Zitieren
APA
Hamano, T., & Fukagawa, M. (2024). Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis. Kidney International. https://doi.org/10.1016/j.kint.2024.06.003
Vancouver
Hamano T, Fukagawa M. Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis. Kidney International. 2024. doi:10.1016/j.kint.2024.06.003
BibTeX
@article{Hamano2024,
author = {Hamano, Takayuki and Fukagawa, Masafumi},
title = {Results of the EPISODE trial plead for reasonable practice-based serum phosphate lowering in patients on dialysis},
journal = {Kidney International},
year = {2024},
doi = {10.1016/j.kint.2024.06.003}
}
EUVIMED